Pharmaceuticals News & Press Release Distribution

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...

2022-07-06 18:17 5546

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene ") and HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based inAustralia, was ...

2022-07-06 12:00 2366

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...

2022-07-06 08:10 4950

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

* Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 inEurope GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf...

2022-07-05 23:37 4670

EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement

FUKUOKA, Japan, July 5, 2022 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") with Mitsubishi Tanabe Pharma Corporation (Headquarters:Osaka, Representative Director: Hiro...

2022-07-05 15:00 2539

Endurance RP Limited (SEHK:0575.HK) Operational Update on the PE Prevention Drug Fortacin™ / Senstend™

Phase 3 Study in China is Estimated to Complete in November 2022 HONG KONG, July 5, 2022 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to provide updates on the PE prevention drug - Fo...

2022-07-05 12:06 4222

ClinChoice Raises $150 mm Series E Round Financing, Further Strengthening its Global Services Capabilities

PHILADELPHIA, July 4, 2022 /PRNewswire/ -- Recently, ClinChoice announced the successful completion of its $150 mm Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders, including Lilly A...

2022-07-05 09:20 3011

ClinChoice Raises $150 mm Series E Round Financing, Further Strengthening its Global Services Capabilities

Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia

This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs inChina. ARVN003 is expected to be the first approved drug for presbyopia inChina. SHANGHAI, July 4, 2022 /PRNew...

2022-07-04 22:14 3144

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with advanced ...

2022-07-04 19:30 5830

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

LACHEN, Switzerland, July 4, 2022 /PRNewswire/ -- * Octapharma to present new clinical and scientific data from across Octapharma's haematology and critical care portfolios during the ISTH 2022 Congress * Data to be presented in 11 poster presentations and during two Supported Symposia * N...

2022-07-04 18:00 4017

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...

2022-07-04 13:34 3090

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection, which was initiated by Shangh...

2022-07-04 08:10 3758

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis

SAN FRANCISCO and SUZHOU, China, July 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ot...

2022-07-04 08:00 4073

Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China

Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic approach to developing a functional cure for HBV ...

2022-07-04 07:10 4558

ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment ofPaul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," s...

2022-07-01 22:00 5584

GSK Spreads Awareness on Vaccine-Preventable Diseases, Attempting to Bridge the Vaccination Gap in Malaysia

Building public trust and educating on the importance of getting vaccinated KUALA LUMPUR, Malaysia, July 1, 2022 /PRNewswire/ -- GSK is a science-led global healthcare company, delivering vaccines that help protect people at all stages of life. GSK's new purpose is to unite science, technology an...

2022-07-01 09:16 3666

GSK Spreads Awareness on Vaccine-Preventable Diseases, Attempting to Bridge the Vaccination Gap in Malaysia

Fosun's Businesses Shows Strong Recovery Momentum as Consumption Regains Vitality and Tourism Industry Continues to Recover

HONG KONG, June 30, 2022 /PRNewswire/ -- The Bund Finance Center (BFC) in Shanghai officially resumed dine-in services at restaurants starting from 29 June. At present, Fosun's businesses and shopping centers inShanghai, including the BFC, Yuyuan Tourist Mart, Forte Woli City, and Orstar City Zhe...

2022-06-30 20:43 4928

Fosun's Businesses Shows Strong Recovery Momentum as Consumption Regains Vitality and Tourism Industry Continues to Recover

HONG KONG, June 30, 2022 /PRNewswire/ -- The Bund Finance Center (BFC) in Shanghai officially resumed dine-in services at restaurants starting from 29 June. At present, Fosun's businesses and shopping centers inShanghai, including the BFC, Yuyuan Tourist Mart, Forte Woli City, and Orstar City Zhe...

2022-06-30 20:16 4801

Australian developed VIRALEZE™ nasal spray relaunched by LloydsPharmacy in the UK

MELBOURNE, Australia, June 30, 2022 /PRNewswire/ -- UK consumers will again be able to buy VIRALEZE™, an easy-to-use barrier nasal spray, from LloydsPharmacy, following its relaunch online, with instore availability to follow shortly. Extensive antiviral testing undertaken at the globally renowne...

2022-06-30 12:41 2393

Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918

SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm...

2022-06-30 10:41 2450